---
title: "Brain Tumors"
order: 2
category: "Neurosurgery"
---

# Brain Tumors

## Overview

Brain tumors encompass a heterogeneous group of intracranial neoplasms arising from brain parenchyma, meninges, cranial nerves, or pituitary gland. Primary brain tumors originate within the central nervous system, while metastatic tumors spread from systemic cancers. Management requires multidisciplinary collaboration between neurosurgery, neuro-oncology, radiation oncology, and neuropathology. Treatment goals include maximal safe resection, tissue diagnosis, symptom relief, and prolonged survival while preserving neurologic function.

## Classification and Epidemiology

### WHO Classification of CNS Tumors (2021)

**Major Categories**
- **Gliomas**: Astrocytomas, oligodendrogliomas, ependymomas
- **Meningiomas**: Benign, atypical, malignant
- **Medulloblastomas**: Pediatric cerebellar tumors
- **Nerve sheath tumors**: Schwannomas, neurofibromas
- **Pituitary tumors**: Adenomas, craniopharyngiomas
- **Metastatic tumors**: Lung, breast, melanoma, renal, colorectal

**Molecular Classification**
- **IDH mutation status**: Prognostic marker in gliomas
- **1p/19q codeletion**: Oligodendrogliomas, better prognosis
- **MGMT promoter methylation**: Predicts chemotherapy response
- **BRAF mutations**: Pediatric low-grade gliomas

### Epidemiology

**Incidence**
- Primary brain tumors: 23 per 100,000 annually
- Metastatic tumors: 4-5× more common than primary

**Age Distribution**
- **Adults**: Glioblastoma (most common), meningioma, metastases
- **Children**: Medulloblastoma, pilocytic astrocytoma, ependymoma

**Survival**
- **5-year survival**:
  - Glioblastoma: 5-10%
  - Anaplastic astrocytoma: 25-30%
  - Low-grade glioma: 50-70%
  - Meningioma (benign): >90%

## Clinical Presentation

### General Symptoms

**Increased Intracranial Pressure**
- Headache (50%): Worse in morning, with Valsalva, progressive
- Nausea, vomiting
- Papilledema
- Altered mental status
- Cushing's triad (late): Hypertension, bradycardia, irregular respirations

**Seizures** (30-50%)
- Focal or generalized
- New-onset seizures in adults: Red flag for brain tumor
- More common with slow-growing tumors (low-grade gliomas, meningiomas)

**Cognitive Changes**
- Memory impairment
- Personality changes
- Confusion, decreased concentration

### Focal Neurologic Deficits (Location-Dependent)

**Frontal Lobe**
- Personality changes, disinhibition
- Executive dysfunction
- Hemiparesis (motor cortex)
- Broca aphasia (dominant hemisphere)

**Temporal Lobe**
- Memory impairment
- Wernicke aphasia (dominant hemisphere)
- Visual field deficits (superior quadrantanopia)
- Complex partial seizures

**Parietal Lobe**
- Sensory deficits
- Neglect (non-dominant hemisphere)
- Gerstmann syndrome (dominant): Acalculia, agraphia, finger agnosia, left-right disorientation

**Occipital Lobe**
- Visual field deficits (homonymous hemianopia)
- Visual hallucinations

**Cerebellum**
- Ataxia, dysmetria
- Nystagmus
- Dysdiadochokinesia
- Obstructive hydrocephalus

**Brainstem**
- Cranial nerve palsies
- Long tract signs
- Respiratory compromise

**Pituitary**
- Visual field deficits (bitemporal hemianopia from optic chiasm compression)
- Endocrine dysfunction
- Headache

## Diagnostic Evaluation

### Neuroimaging

**MRI Brain with Contrast** (Gold Standard)
- **T1-weighted**: Anatomic detail
- **T2-weighted/FLAIR**: Edema, infiltration
- **Contrast enhancement** (gadolinium): Disrupted blood-brain barrier
  - Glioblastoma: Ring-enhancing lesion
  - Meningioma: Homogeneous enhancement, "dural tail"
  - Metastases: Multiple enhancing lesions at gray-white junction
- **Diffusion-weighted imaging (DWI)**: Abscess (restricted diffusion), cystic tumors
- **Perfusion imaging**: Tumor grade, distinguish tumor recurrence from radiation necrosis
- **MR spectroscopy**: Metabolic profile (Cho/NAA ratio elevated in high-grade gliomas)

**Advanced MRI**
- **Functional MRI (fMRI)**: Map eloquent cortex (motor, language) preoperatively
- **Diffusion tensor imaging (DTI)**: White matter tracts, surgical planning

**CT Head**
- Less sensitive than MRI
- Useful for: Calcification (oligodendroglioma, meningioma), bone erosion, emergency settings
- Contrast-enhanced CT if MRI contraindicated

**PET Scan**
- **FDG-PET**: Tumor metabolism, distinguish recurrence from radiation necrosis
- **Amino acid PET** (MET, FET): More specific for tumor tissue

### Laboratory Tests

- Complete blood count, comprehensive metabolic panel
- Coagulation studies (preoperative)
- Pituitary function tests (if pituitary/sellar tumor)
- Tumor markers: AFP, beta-hCG (germ cell tumors)

### Biopsy vs. Resection

**Stereotactic Biopsy**
- **Indications**:
  - Deep-seated lesion (thalamus, brainstem, basal ganglia)
  - Eloquent location (high surgical risk)
  - Multiple lesions (lymphoma, metastases)
  - Diagnostic uncertainty
  - Medical comorbidities precluding craniotomy
- **Technique**: Frame-based or frameless stereotactic guidance
- **Risks**: Hemorrhage (1-3%), non-diagnostic sample (5-10%)

**Resection**
- **Indications**:
  - Accessible lesion
  - Symptomatic mass effect
  - Hydrocephalus
  - Resectable tumor type (meningioma, low-grade glioma)
- **Goals**: Maximal safe resection, cytoreduction, symptom relief

## Gliomas

### Low-Grade Gliomas (WHO Grade 2)

**Subtypes**
- **Diffuse astrocytoma**: IDH-mutant (better prognosis), IDH-wildtype
- **Oligodendroglioma**: IDH-mutant, 1p/19q-codeleted (best prognosis)

**Clinical Presentation**
- Seizures (70-90%)
- Slow progression of symptoms
- Often diagnosed incidentally

**Imaging**
- T2/FLAIR hyperintense, infiltrative
- Minimal or no contrast enhancement
- Little mass effect

**Management**

**Observation**
- Small, asymptomatic tumors
- Elderly, poor surgical candidates

**Surgical Resection**
- **Goal**: Maximal safe resection (extent of resection correlates with survival)
- **Techniques**: Awake craniotomy for eloquent area tumors, intraoperative mapping
- **Outcomes**: Seizure control (70-80%), improved survival

**Adjuvant Therapy**
- **Chemotherapy**: Temozolomide, PCV (procarbazine, lomustine, vincristine) for oligodendroglioma
- **Radiation**: Reserved for high-risk features (age >40, large size, incomplete resection) or progression

**Prognosis**
- Median survival:
  - Oligodendroglioma (1p/19q-codeleted): 10-15 years
  - Astrocytoma (IDH-mutant): 7-10 years
  - Astrocytoma (IDH-wildtype): Behaves like glioblastoma, <3 years

### High-Grade Gliomas (WHO Grade 3-4)

**Glioblastoma (Grade 4)** - Most Common Primary Malignant Brain Tumor

**Pathology**
- Highly malignant, infiltrative
- Necrosis, microvascular proliferation
- IDH-wildtype (90%), IDH-mutant (10%)

**Imaging**
- Ring-enhancing lesion with central necrosis
- Extensive vasogenic edema (FLAIR hyperintensity)
- Mass effect, midline shift
- "Butterfly" glioma: Crosses corpus callosum

**Management**

**Surgical Resection**
- **Goal**: Maximal safe resection (extent correlates with survival)
  - Gross total resection (GTR): Median survival 15 months
  - Subtotal resection (STR): Median survival 11 months
- **5-ALA fluorescence**: Tumor visualization intraoperatively
- **Intraoperative MRI**: Confirm extent of resection
- **Awake craniotomy**: For eloquent location tumors

**Stupp Protocol** (Standard of Care)
1. **Surgical resection**: Maximal safe
2. **Concurrent chemoradiation**:
   - Radiation: 60 Gy in 30 fractions (6 weeks)
   - Temozolomide: 75 mg/m² daily during radiation
3. **Adjuvant chemotherapy**:
   - Temozolomide: 150-200 mg/m² days 1-5 of 28-day cycle × 6 cycles

**MGMT Methylation**
- **Methylated**: Better response to temozolomide, longer survival (21 months vs 15 months)
- **Unmethylated**: May consider other regimens or clinical trials

**Tumor-Treating Fields (TTFields)**
- Optune device: Alternating electric fields
- Approved for newly diagnosed and recurrent glioblastoma
- Modest survival benefit (2-3 months) when added to chemotherapy

**Recurrence Management**
- **Re-resection**: If feasible, improves survival
- **Bevacizumab** (Avastin): Anti-VEGF antibody, palliative
- **Re-radiation**: Stereotactic radiosurgery
- **Clinical trials**: Immunotherapy (checkpoint inhibitors, vaccines), targeted therapy

**Prognosis**
- Median survival: 15-18 months with Stupp protocol
- 2-year survival: 25-30%
- 5-year survival: 5-10%

**Anaplastic Astrocytoma (Grade 3)**
- IDH-mutant: Better prognosis (median survival 3-5 years)
- IDH-wildtype: Similar to glioblastoma (median survival 1-2 years)

### Ependymomas

**Classification**
- **Supratentorial**: Adults
- **Posterior fossa**: Children (most common location)
- **Spinal cord**: Adults

**Management**
- **Surgical resection**: GTR is goal (prognostic factor)
- **Radiation**: Adjuvant therapy, especially if subtotal resection
- **Chemotherapy**: Limited role

**Prognosis**
- 5-year survival: 50-70% (depends on extent of resection, location, grade)

## Meningiomas

### Pathology

**WHO Grading**
- **Grade I (Benign)**: 80-85%
- **Grade II (Atypical)**: 10-15%, higher recurrence
- **Grade III (Malignant/Anaplastic)**: <5%, aggressive, metastatic potential

**Origin**
- Arise from arachnoid cap cells
- Extra-axial (outside brain parenchyma)

**Common Locations**
- Convexity (parasagittal)
- Falx cerebri
- Skull base (sphenoid wing, olfactory groove, cerebellopontine angle)
- Spinal canal

### Clinical Presentation

- Seizures (30-40%)
- Focal neurologic deficits (location-dependent)
- Headache
- Cognitive changes
- Often incidentally discovered on imaging

### Imaging

**MRI**
- Homogeneously enhancing extra-axial mass
- **"Dural tail"**: Dural enhancement extending from tumor
- Hyperostosis (bone thickening) adjacent to tumor
- Calcification common

**CT**
- Hyperdense mass
- Calcification, hyperostosis

### Management

**Observation**
- Small, asymptomatic tumors
- Elderly, poor surgical candidates
- Slow growth rate (1-2 mm/year)
- Serial imaging

**Surgical Resection**

**Indications**
- Symptomatic tumors
- Progressive growth
- Large size, mass effect
- Young patients

**Simpson Grading** (Extent of Resection)
- **Grade I**: Complete removal including dura and bone (lowest recurrence, 10%)
- **Grade II**: Complete removal + coagulation of dural attachment (20%)
- **Grade III**: Complete removal, no dura/bone (30%)
- **Grade IV**: Subtotal resection (40%)
- **Grade V**: Biopsy only (high recurrence)

**Surgical Technique**
- Craniotomy centered over tumor
- Devascularize tumor: Coagulate dural attachment, feeding arteries
- Internal debulking, piecemeal removal
- Resect dura, bone if involved
- Duraplasty with graft if dural resection

**Skull Base Meningiomas**
- Complex anatomy, cranial nerves, vascular structures
- Often require skull base approaches
- Higher morbidity, may require staged resections

**Adjuvant Therapy**

**Radiation**
- **Indications**: Subtotal resection, atypical/malignant grade, recurrent
- **Stereotactic radiosurgery (SRS)**: Small tumors (<3 cm), skull base location
- **Fractionated radiation**: Larger tumors, atypical/malignant

**Chemotherapy**
- Limited role, reserved for malignant, progressive tumors

### Prognosis

- **Grade I**: 10-year recurrence-free survival 80-90% after GTR
- **Grade II (Atypical)**: 50-60% recurrence-free survival at 10 years
- **Grade III (Malignant)**: High recurrence, 50% mortality at 5 years

## Pituitary Tumors

### Classification

**Functional Adenomas** (Hormone-Secreting)
- **Prolactinoma** (40%): Hyperprolactinemia
- **Growth hormone (GH)**: Acromegaly (adults), gigantism (children)
- **ACTH**: Cushing's disease
- **TSH**: Hyperthyroidism (rare)

**Non-Functional Adenomas** (40%)
- Mass effect symptoms (visual, headache, hypopituitarism)

**Size Classification**
- **Microadenoma**: <10 mm
- **Macroadenoma**: ≥10 mm

### Clinical Presentation

**Endocrine Dysfunction**
- **Hyperprolactinemia**: Amenorrhea, galactorrhea (females), hypogonadism (males)
- **Acromegaly**: Enlarged hands/feet, coarse facial features, diabetes, hypertension
- **Cushing's disease**: Weight gain, hypertension, diabetes, moon facies, striae

**Mass Effect**
- **Visual field deficits**: Bitemporal hemianopia (optic chiasm compression)
- **Hypopituitarism**: Hypogonadism, hypothyroidism, adrenal insufficiency
- **Headache**

**Pituitary Apoplexy**
- Sudden hemorrhage or infarction of pituitary tumor
- Severe headache, visual loss, altered consciousness
- Endocrine crisis (adrenal insufficiency)
- **Emergency**: Requires urgent decompression

### Diagnostic Evaluation

**Imaging**
- **MRI pituitary with contrast**: T1 pre- and post-contrast, thin cuts
  - Microadenoma: Hypointense lesion on T1
  - Macroadenoma: Enhancing mass, suprasellar extension, optic chiasm compression
- **CT**: Bone erosion, calcification

**Endocrine Testing**
- **Prolactin**: Elevated (prolactinoma)
  - >200 ng/mL: Prolactinoma
  - Mild elevation (<100 ng/mL): Stalk effect from non-functional tumor
- **IGF-1, oral glucose tolerance test**: Acromegaly
- **24-hour urinary cortisol, dexamethasone suppression test**: Cushing's disease
- **TSH, free T4, testosterone, cortisol, FSH, LH**: Assess pituitary function

**Visual Field Testing**
- Formal perimetry to document deficits

### Management

**Prolactinoma**

**Medical Management** (First-Line)
- **Dopamine agonists**: Cabergoline (preferred) or bromocriptine
- Normalizes prolactin in 80-90%
- Tumor shrinkage in 70-80%
- Lifelong therapy typically required

**Surgical Indications**
- Drug intolerance or resistance
- Apoplexy
- CSF leak
- Visual compromise despite medical therapy

**Acromegaly and Cushing's Disease**
- **Surgical resection**: First-line treatment (transsphenoidal surgery)
- Medical therapy if surgical failure or recurrence

**Non-Functional Adenomas**
- **Surgery**: Indicated if symptomatic (visual loss, hypopituitarism) or growing
- **Observation**: Small, asymptomatic tumors

### Surgical Technique: Transsphenoidal Surgery

**Approach**
- **Endoscopic endonasal**: Most common, direct approach through sphenoid sinus
- **Microscopic sublabial**: Historical, less common now

**Steps**
1. **Nasal phase**: Access sphenoid sinus through nasal cavity
2. **Sphenoid phase**: Open sphenoid sinus, identify sella turcica
3. **Sellar phase**: Open sellar floor, remove tumor
4. **Closure**: Repair sellar floor, prevent CSF leak (fat graft, nasoseptal flap)

**Complications**
- **CSF leak** (5-10%): May require repair, lumbar drain
- **Hypopituitarism** (10-20%): May require hormone replacement
- **Diabetes insipidus** (10-20%): Transient or permanent, requires DDAVP
- **Vision loss** (<1%): Optic nerve/chiasm injury
- **Vascular injury** (<1%): Carotid artery, cavernous sinus
- **Meningitis** (1-2%)

### Outcomes

- **Surgical cure rates**:
  - Microadenomas: 80-90%
  - Macroadenomas: 50-60%
- **Recurrence**: 10-20% at 10 years
- **Visual improvement**: 70-90% if preoperative deficits

### Craniopharyngioma

**Characteristics**
- Benign but locally aggressive tumor
- Arises from remnants of Rathke's pouch
- Bimodal age distribution: Children (5-10 years), adults (50-70 years)

**Imaging**
- Mixed cystic-solid mass in suprasellar region
- Calcification (90% in children, 40% in adults)

**Management**
- **Surgical resection**: GTR if possible, high morbidity
- **Limited resection + radiation**: For large, adherent tumors
- **Cyst aspiration + Ommaya reservoir**: Intracystic therapy (bleomycin, interferon)

**Complications**
- Hypopituitarism (universal after treatment)
- Diabetes insipidus
- Visual deficits
- Hypothalamic dysfunction: Obesity, behavioral changes

## Metastatic Brain Tumors

### Epidemiology

**Primary Tumor Sites**
- **Lung** (40-50%): Small cell and non-small cell
- **Breast** (15-20%)
- **Melanoma** (10-15%): Highest propensity to metastasize to brain
- **Renal cell carcinoma** (5-10%)
- **Colorectal** (5%)
- **Unknown primary** (10-15%)

**Incidence**
- 10× more common than primary brain tumors
- 20-40% of cancer patients develop brain metastases

### Clinical Presentation

- Similar to primary tumors: Headache, seizures, focal deficits
- Often multiple lesions (50-70%)
- Systemic cancer known in 80-90%

### Imaging

**MRI Brain with Contrast**
- Multiple enhancing lesions at gray-white junction (vascular watershed areas)
- Circumscribed, round
- Extensive vasogenic edema
- **Melanoma**: May have T1 hyperintensity (hemorrhagic)

**Staging Workup**
- CT chest/abdomen/pelvis
- PET scan
- Identify primary tumor if unknown

### Management

**Prognostic Scoring: GPA (Graded Prognostic Assessment)**
- Age, KPS, number of metastases, extracranial disease control
- Guides treatment decisions

**Corticosteroids**
- **Dexamethasone**: Reduces vasogenic edema, symptom relief
- Start before definitive treatment

**Surgical Resection**

**Indications**
- Single or limited metastases (1-3)
- Good performance status (KPS ≥70)
- Controlled or controllable systemic disease
- Large lesion (>3 cm), symptomatic mass effect
- Unknown primary (tissue diagnosis needed)
- Radioresistant tumor (melanoma, renal cell carcinoma)

**Benefits**
- Immediate symptom relief
- Tissue diagnosis
- Improved local control vs. radiation alone
- Survival benefit in appropriate patients

**Technique**
- Craniotomy, piecemeal tumor removal
- Resect to tumor-brain interface (metastases are well-circumscribed)

**Outcomes**
- Median survival:
  - Surgery + radiation: 10-12 months
  - Radiation alone: 4-6 months
- Improved with systemic therapy advances (immunotherapy, targeted therapy)

**Stereotactic Radiosurgery (SRS)**

**Indications**
- Multiple metastases (1-10 lesions)
- Small lesions (<3 cm)
- Deep or eloquent location
- Surgically inaccessible

**Technique**
- Single high-dose radiation (Gamma Knife, CyberKnife, LINAC)
- Outpatient, non-invasive

**Efficacy**
- Local control: 80-90% at 1 year
- Survival similar to surgery for small lesions

**Whole Brain Radiation Therapy (WBRT)**

**Indications**
- Multiple metastases (>10)
- Leptomeningeal disease
- Poor performance status

**Side Effects**
- Cognitive decline (especially delayed, >6 months)
- Fatigue, alopecia

**WBRT After SRS**
- Debate: SRS alone vs. SRS + WBRT
- SRS alone: Better cognitive outcomes, increased distant brain recurrence (requires salvage SRS)

**Systemic Therapy**
- **Chemotherapy**: Most agents do not cross blood-brain barrier
- **Targeted therapy**: EGFR inhibitors (lung), HER2 inhibitors (breast), BRAF inhibitors (melanoma)
- **Immunotherapy**: Checkpoint inhibitors (melanoma, lung, renal cell carcinoma)
  - Improved outcomes, may delay or avoid radiation

## Surgical Techniques and Technology

### Awake Craniotomy

**Indications**
- Tumors in eloquent cortex (motor, language)
- Maximize resection while preserving function

**Technique**
- **Asleep-awake-asleep**: Anesthesia for craniotomy, awake for mapping, re-sedation for closure
- **Language mapping**: Object naming, counting, reading during resection
- **Motor mapping**: Direct cortical stimulation, monitor movements

**Advantages**
- Real-time functional assessment
- Higher extent of resection in eloquent areas
- Lower neurologic morbidity

### Intraoperative Mapping and Monitoring

**Direct Cortical Stimulation**
- Identify motor and language cortex
- Avoid injury to eloquent areas

**Motor Evoked Potentials (MEPs)**
- Monitor motor pathways during resection
- Warn of impending motor deficit

**Somatosensory Evoked Potentials (SSEPs)**
- Monitor sensory pathways

**5-Aminolevulinic Acid (5-ALA) Fluorescence**
- Glioblastoma cells fluoresce under blue light
- Improved extent of resection

**Intraoperative MRI**
- Verify extent of resection in real-time
- Allows further resection if residual tumor

### Neuronavigation

- Image-guided surgery using preoperative MRI/CT
- Stereotactic localization of tumor, eloquent structures, trajectories

## Key Points

1. **Glioblastoma** is the most common malignant primary brain tumor; standard treatment is maximal safe resection followed by concurrent chemoradiation and adjuvant temozolomide (Stupp protocol).

2. **Extent of resection** correlates with survival in gliomas; gross total resection (GTR) preferred when safe.

3. **MGMT promoter methylation** predicts response to temozolomide in glioblastoma; methylated tumors have better prognosis.

4. **Low-grade gliomas** (WHO Grade 2) with IDH mutation and 1p/19q codeletion (oligodendrogliomas) have best prognosis (median survival 10-15 years).

5. **Meningiomas** are extra-axial tumors; Simpson Grade I-II resection (including dura and bone) has lowest recurrence; observation appropriate for small, asymptomatic tumors.

6. **Prolactinomas** are treated medically (dopamine agonists) as first-line; surgery reserved for drug intolerance, resistance, or apoplexy.

7. **Transsphenoidal surgery** is standard approach for pituitary adenomas; CSF leak (5-10%) and hypopituitarism (10-20%) are common complications.

8. **Metastatic brain tumors** are more common than primary brain tumors; treatment includes surgical resection (single lesion, good performance status) or stereotactic radiosurgery (multiple lesions, <3 cm).

9. **Awake craniotomy** with intraoperative mapping allows maximal safe resection of tumors in eloquent cortex (motor, language) while preserving function.

10. **Immunotherapy and targeted therapy** have improved outcomes for brain metastases from melanoma, lung cancer, and renal cell carcinoma; may delay or avoid radiation.

## References

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.

2. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.

3. Ostrom QT, Cioffi G, Waite K, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1-iii105.

4. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251.

5. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22-39.

6. Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401-409.

7. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494-500.

8. Molina CA, Zadeh G, Colquhoun IR. Clinical presentation, imaging, and management of metastatic brain tumors. Neurosurg Clin N Am. 2011;22(1):27-36.

9. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401.

10. Casanueva FF, Barkan AL, Buchfelder M, et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary. 2017;20(5):489-498.
